Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate ...

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

A new study led by UCL researchers suggests that making cancer cells more visible to the immune system could broaden the ...

Analysis and data generation pipeline for the "Artificial Intelligence Perceives Marginal Gains from MHC Haplotype Data in Antigen Presentation Predictions" paper (in peer review). Supporting data and ...

Background: Adoptive transfer of splenocytes from mice, post-myocardial infarction (MI), into naïve recipients has been shown to induce adverse cardiac remodeling along the cardiosplenic axis. The ...

Transplantation of organs or tissues between genetically nonidentical individuals of the same species (and different species) is plagued by rejection and its associated problems. "Foreignness" is ...

Study introduces TRACeR-I, a protein platform with broad HLA compatibility, paving the way for advanced immune response engineering and disease-specific targeting. Study: Targeting peptide antigens ...

Researchers have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform ...

Philadelphia, December 13, 2024 – Researchers from Children’s Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for ...

Researchers from Children's Hospital of Philadelphia (CHOP) and Stanford University have revealed the molecular structure of TRACeR-I, a protein platform for reprogramming immune responses. A better ...